Introduction Palbociclib is an oral targeted anticancer drug marketed under the brand name Ibrance. Pharmacologically, palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor, commonly called a CDK4/6 inhibitor. Cell-cycle control is one of the most important concepts in cancer pharmacology. Normal cells divide only after receiving controlled growth signals. Cancer cells often escape these … Read more
Introduction Verzenio is the brand name of abemaciclib, an oral targeted anticancer drug used in selected patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. Pharmacologically, Verzenio belongs to the cyclin-dependent kinase 4 and 6 inhibitor class, commonly called CDK4/6 inhibitors. CDK4 and CDK6 are key enzymes that regulate progression of cells … Read more
Introduction Abemaciclib is an oral targeted anticancer drug used mainly in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. It is marketed under the brand name Verzenio. Pharmacologically, abemaciclib belongs to the cyclin-dependent kinase 4 and 6 inhibitor class, commonly abbreviated as CDK4/6 inhibitors. CDK4 and CDK6 are important enzymes involved in cell-cycle … Read more
